<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CCM2 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CCM2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cerebral Cavernous Malformation 2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>7p13</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10585](https://www.ncbi.nlm.nih.gov/gene/10585)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607929](https://www.omim.org/entry/607929)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000168781</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9BSQ5](https://www.uniprot.org/uniprot/Q9BSQ5)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Cerebral Cavernous Malformation](/diseases/cerebral-cavernous-malformation), [Stroke](/diseases/stroke), [Alzheimer's Disease](/diseases/alzheimers-disease)</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CCM2 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CCM2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cerebral Cavernous Malformation 2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>7p13</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10585](https://www.ncbi.nlm.nih.gov/gene/10585)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607929](https://www.omim.org/entry/607929)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000168781</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9BSQ5](https://www.uniprot.org/uniprot/Q9BSQ5)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Cerebral Cavernous Malformation](/diseases/cerebral-cavernous-malformation), [Stroke](/diseases/stroke), [Alzheimer's Disease](/diseases/alzheimers-disease)</td></tr>
</table>
</div>
CCM2 (Cerebral Cavernous Malformation 2), also known as malcavernin or MGC4606, encodes an essential scaffold protein that plays a critical role in vascular development, endothelial cell function, and blood-brain barrier integrity. CCM2 is a core component of the CCM complex, a heterotrimeric protein assembly that also includes CCM1 (KRIT1) and CCM3 (PDCD10). This complex regulates multiple signaling pathways including RhoA/ROCK, TGF-β, MAPK/ERK, and VEGF signaling, all essential for maintaining endothelial junction integrity and vascular homeostasis. Loss-of-function mutations in CCM2 cause familial cerebral cavernous malformation (CCM), a neurovascular disease characterized by dilated capillary channels that cause seizures, hemorrhagic stroke, and progressive neurological deficits. Beyond CCM disease, CCM2 has emerged as important in neurodegenerative diseases through its regulation of blood-brain barrier function and neurovascular unit integrity, making it relevant to Alzheimer's disease, Parkinson's disease, and other neurological disorders.
The CCM2 gene is located on chromosome 7p13 and encodes a protein of approximately 444 amino acids. The gene consists of 10 exons spanning approximately 26 kb of genomic DNA. Multiple transcript variants are generated through alternative splicing, resulting in isoforms with distinct tissue distribution and functional properties.
The CCM2 promoter contains regulatory elements including a TATA-less promoter with initiator-driven transcription, Sp1 binding sites for ubiquitous expression regulation, VEGF-responsive elements for endothelial-specific expression, and shear stress response elements for flow-dependent regulation.
CCM2 shows significant evolutionary conservation with mammalian orthologs sharing >90% amino acid identity. The phosphotyrosine-binding (PTB) domain is highly conserved, the C-terminal tail contains conserved regulatory motifs, and the FF domain (two phenylalanine residues) is unique to CCM2 among CCM family members.
CCM2 contains several functional domains critical for its scaffold function:
CCM2 exhibits broad expression with highest levels in vascular tissue. High expression is found in endothelial cells (arterial, venous, and capillary), brain (cortex, hippocampus, cerebellum), heart (myocardium and vasculature), and lung (pulmonary vasculature). Moderate expression is observed in liver (sinusoidal endothelium), kidney (glomerular capillaries), and spleen (splenic sinusoids).
Within the central nervous system, CCM2 shows specific patterns in cerebral cortex (layer 1-6 neurons and vasculature), hippocampus (CA1-3 regions, dentate gyrus), cerebellum (Purkinje cells, granule cells), and blood-brain barrier (endothelial cells and pericytes).
CCM2 serves as a central scaffold that bridges CCM1 and CCM3 to form the CCM complex. This enables complex assembly, directs the complex to cell junctions, and coordinates multiple signaling pathways.
CCM2 critically regulates vascular permeability. For tight junction regulation, CCM2 controls claudin expression, regulates occludin localization, and modulates junctional adhesion molecules. For adherens junction maintenance, CCM2 controls VE-cadherin dynamics, regulates β-catenin association, and maintains cytoskeletal anchoring.
CCM2 is a key regulator of RhoA signaling by promoting RhoA GTP loading, activating downstream ROCK effector kinases, regulating cytoskeletal dynamics including actin stress fiber formation, and controlling vascular smooth muscle contractile tone.
CCM2 modulates TGF-β pathway by modulating TGF-β receptor function, regulating SMAD signaling as the downstream transcription factor, and controlling angiogenesis through vessel formation.
CCM2 intersects with VEGF pathways by modulating VEGFR2 signaling, controlling angiogenesis through new vessel formation, and promoting endothelial survival for vascular maintenance.
CCM2 is one of three genes causative for familial CCM. The pathogenesis involves loss-of-function mutations leading to vascular malformations comprised of dilated capillary channels with multilayered endothelium without smooth muscle and abnormal vessel walls lacking proper barrier function. Clinical manifestations include seizures (30-50% of patients), hemorrhagic stroke (25-40%), headaches (20-30%), focal neurological deficits (15-25%), and cognitive impairment (10-20%). Genetics show autosomal dominant inheritance with approximately 10-15% of familial cases involving CCM2, incomplete penetrance, and variable expressivity.
CCM2 mutations increase cerebrovascular risk through intracranial hemorrhage, cerebral bleeding events, secondary stroke from CCM lesions, and cavernous malformation rupture.
CCM2 has emerged as relevant to AD through several mechanisms. For blood-brain barrier dysfunction, CCM2 regulates BBB integrity, is reduced in AD brain vasculature, contributes to vascular leak, and enables peripheral protein entry. For neurovascular unit dysfunction, endothelial dysfunction and pericyte coverage abnormalities are observed along with increased BBB permeability. Therapeutic implications include CCM2 restoration as a therapeutic strategy and vascular protective approaches.
CCM2 deficiency promotes inflammation by increasing leukocyte adhesion, enhancing immune cell infiltration, causing cytokine dysregulation, and activating microglia.
CCM2 interacts with numerous proteins. Core complex members include CCM1/KRIT1 as the primary binding partner and CCM3/PDCD10 as the third complex component. Signaling proteins include RhoA for small GTPase regulation, ROCK1/ROCK2 for kinase effectors, TGF-β receptors for growth factor signaling, and MEKK3 for MAP kinase pathway. Cytoskeletal proteins include actin for cytoskeletal dynamics and tubulin for microtubule organization.
CCM2 intersects with multiple pathways including RhoA/ROCK as the primary signaling axis, TGF-β for growth factor signaling, MAPK/ERK for proliferation and survival, and VEGF for angiogenesis regulation.
CCM2-related therapeutics under investigation include RhoA/ROCK inhibitors such as fasudil in clinical trials for CCM and Y-27632 in preclinical studies, as well as VEGF modulation approaches including bevacizumab for anti-angiogenic therapy and VEGF receptor inhibitors.
Potential therapeutic areas include CCM treatment for reducing lesion burden, stroke prevention through vascular integrity stabilization, and AD therapy through BBB protection.
Key approaches for studying CCM2 include molecular biology (Western blot, qPCR, IP), live imaging for endothelial dynamics, animal models with Ccm2 knockout mice, and patient-derived cells using iPSC endothelial cells.